In the same period a year ago, the company posted a loss of 24 cents a share on sales of $0.2 million.
The stock has fallen 21.15% since the company last reported earnings on Mar. 28. Quarterly estimates have fallen 3 cents a share in the past month.
Vascular Biogen is currently trading at a price-to-forward-earnings ratio of -2.2 based on the 12-month estimates of 3 analysts surveyed by FactSet.
Vascular Biogenics was recently reviewed by the Real Money Pro Quantitative Rating Service. For more information about how you can profit from the service, please click here now.